drugset
drugset / Trial / NCT01692184

Safety and Pharmacokinetics of AVL-292 Following Multiple Doses and the Effect of Food on the Single-dose Pharmacokinetics of AVL-292

NCT01692184 ↗

Phase 1 Completed 54 enrolled Celgene Corporation
RandomizedParallel-groupQuadruple-blindOther

Summary

This is a 2-part study. The first part is to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics of AVL-292 following multiple oral doses; and the second part is to evaluate the effect of food on the pharmacokinetics of a single oral dose of AVL-292.

Timeline

Start
2012-08-01
Primary completion
2012-10-08
Completion
2012-10-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Spebrutinib Small molecule 50 mg Oral
Subject Spebrutinib Small molecule 100 mg Oral
Subject Spebrutinib Small molecule 200 mg Oral
Subject Spebrutinib Small molecule 350 mg Oral

Indications

No indication recorded.